molecular diagnostics

Shares of the molecular diagnostics name Myriad Genetics (NYSE: MYGN) are worth less than what the Street is paying, according to Goldman Sachs.  The Analyst Goldman Sachs analyst Patrick Donnelly initiated coverage of Myriad Genetics with a Sell and $32 price target, implying a 22-...